Press Release
Arcadia Biosciences Receives FDA Approval for SONOVA® GLA Safflower Oil in Cat Food
-- SONOVA GLA offers cat food manufacturers a sustainable, plant-based source of essential omega-6 fatty acid --
Arcadia’s
“The FDA clearance of SONOVA GLA for use in cat food is another example of our proven ability to improve crops’ nutrition and value as ingredients from concept to commercialization, as with our GoodWheat™ platform,” said Raj Ketkar, president and CEO of Arcadia. “SONOVA GLA will allow cat and dog food formulators to respond to consumer demand for natural, plant-based oils as wellness ingredients for their beloved companions.”
Watt Media1 reports that 63 percent of dog food formulations and 46 percent of cat food formulations include functional ingredients that offer special nutritional benefits in terms of general wellness or address specific health concerns such as digestion, joint and cartilage function, immune system strength or dental health. Fueling this trend is America’s increasing attention to health issues, both human and pet, which ties in to an aging and often overweight population.
“Increasing the concentration of omega-6 fatty acid in the safflower
plant by a factor of more than 40x showcases our ability to optimize
plant-based sources of high value health and nutritional ingredients,”
added
Publication in the Federal Register completes the issuance of a new food regulation - Title 21, Code of Federal Regulations (21 CFR), part 573 – Food Additives Permitted in Feed and Drinking Water of Animals – that is “amended § 573.492 (21 CFR 573.492) to allow for the safe use of GLA safflower oil in dry food for adult cats, the current allowable concentration range for gamma-linolenic acid in the additive or the safflower oil blend was amended to incorporate the broader range supported by FAP 2302.”
For more information on Arcadia’s SONOVA GLA for pet food use, visit: www.sonovaglapet.com
About
About Arcadia Specialty Genomics
Arcadia Specialty Genomics is a strategic business unit of
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: Arcadia’s and
its partners’ and affiliates’ ability to develop commercial products
incorporating their traits, and complete the regulatory review process
for such products; Arcadia’s compliance with laws and regulations that
impact Arcadia’s business, and changes to such laws and regulations;
Arcadia’s future capital requirements and ability to satisfy its capital
needs; Arcadia’s ability to develop, enforce and defend its intellectual
property rights; and the other risks set forth in Arcadia’s filings with
the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190315005053/en/
Source:
Arcadia Biosciences
Jeff Bergau
+1-312-217-0419
jeff.bergau@arcadiabio.com